Carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Carcinoma
- Therapeutic area
- Oncology
- carcinoma
- epithelioma
- Other carcinoma
- carcinoma
- carcinoma, malignant
- epithelial carcinoma
- epithelioma malignant
- malignant epithelial neoplasm
- malignant epithelial tumor
- malignant epithelial tumour
- malignant epithelioma
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0004993
- Parent condition
- MONDO:0004992
Related records
Broader conditions (8)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (976)
- Acantholytic squamous cell skin carcinoma
- Acantholytic variant squamous cell breast carcinoma
- Acinar cell carcinoma
- Acinar lung adenocarcinoma
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Acinic cell breast carcinoma
- Acquired cystic disease-associated renal cell carcinoma
- ACTH-producing pituitary gland carcinoma
- Adamantinoid basal cell epithelioma
- Adamantinoma
- Adenoacanthoma
- Adenocarcinoma
- Adenocarcinoma in situ
- Adenocarcinoma of gallbladder and extrahepatic biliary tract
- Adenocarcinoma of skene gland origin
- Adenoid cystic breast carcinoma
- Adenoid cystic carcinoma
- Adenoid cystic carcinoma of oropharynx
Trials (1,838)
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- 11C Topotecan PET Imaging
- 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
- 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
- 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
- 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
- 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
- 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).
- A Beta-only IL-2 ImmunoTherapY Study
- A Biomarker Screening Protocol for Participants With Solid Tumors
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
Approved drugs (13)
- Bicalutamide
- Cinacalcet hydrochloride
- Doxorubicin hydrochloride
- Estramustine phosphate sodium
- Flutamide
- Goserelin acetate
- Hexaminolevulinate hydrochloride
- Irinotecan hydrochloride
- Melphalan
- Paclitaxel
- Thiotepa
- Topotecan hydrochloride
- Valrubicin
Drugs in development (110)
- AEG-35156 Phase 1
- Agatolimod sodium Phase 2
- Aldesleukin Phase 2
- AMG-888 Phase 1
- AMXT-1501 Phase 1
- Anastrozole Phase 2
- Antineoplaston A10 Phase 2
- Atezolizumab Phase 2
- Aumolertinib Phase 1
- Axitinib Phase 1
- AZD-1480 Phase 1
- AZD-4877 Phase 1
- Bavituximab Phase 2
- Belagenpumatucel-L Phase 2
- Belinostat Phase 2
- Berubicin hydrochloride Phase 1
- Bevacizumab Phase 2
- Brigatinib Phase 3
- Brivanib Phase 3
- Cabozantinib Phase 2
Other linked drugs (1)
- Gadopentetate dimeglumine